US FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
The US FDA has expanded approval of Anktiva, offering a new treatment option for certain patients with BCG-unresponsive bladder cancer.
Papillary Bladder Cancer | 16/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy